Phosphorus containing analogues of SAHA as inhibitors of HDACs

Journal of Enzyme Inhibition and Medicinal Chemistry

Michael D. Pun¹  Hsin-Hua Wu¹  Britany N. Kesic¹  Clifford E. Berkman¹  John W. Peters¹  Feyisola P. Olatunji¹ 

[1] Department of Chemistry, Washington State University, Pullman, WA, USA;

关键词: HDAC;    phosphate;    phosphoramidate;    phosphorothiolate;    SAHA;   

DOI  :  10.1080/14756366.2022.2063281

来源: DOAJ

【 摘 要 】

Histone deacetylases (HDACs) are a family of enzymes responsible for regulating DNA transcription by modulating its binding to histone proteins. HDACs are overexpressed in several types of cancers and are recognised as drug targets. Vorinostat, or suberanilohydroxamic acid (SAHA), is an histone deacetylase (HDAC) inhibitor with a hydroxamic acid as a zinc-binding group (ZBG), and it has been FDA approved for the treatment of T-cell lymphoma. In this work, phosphorus-based SAHA analogues were synthesised to assess their zinc-binding effectiveness compared to the hydroxamic acid of SAHA. Specifically, we examined phosphate, phosphoramidate and phosphorothiolate groups as isosteres of the canonical hydroxamic acid motif of conventional HDAC inhibitors. The compounds were screened for binding to HDAC enzymes from HeLa cell lysate. The most potent derivatives were then screened against HDAC3 and HDAC8 isoforms. HDAC inhibition assays demonstrated that these phosphorus-based SAHA analogs exhibited slow binding to HDACs but with greater potency than phosphonate SAHA analogs examined previously. All compounds inhibited HDACs, the most potent having an IC50 of 50 µM.

【 授权许可】

Unknown